Figure 3From: Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing Mean time spent ≥50% Cmax for OROS hydromorphone ER and IR hydromorphone. Panels show mean time spent ≥50% Cmax after single doses of OROS hydromorphone ER and 4 doses of IR hydromorphone (a), and at steady state (b). Cmax, maximum plasma concentration; ER, extended-release; IR, immediate-release.Back to article page